Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity

作者：Li Na; Mu Lili; Wang Jinghua; Zhang Jia; Xie Xiaoli; Kong Qingfei; Tang Wei; Yao Xiuhua; Liu Yumei; Wang Lihua; Wang Guangyou; Wang Dandan; Jin Lianhong; Sun Bo; Li Hulun^*

来源：European Journal of Immunology, 2012, 42(5): 1140-1151.

DOI：10.1002/eji.201142088

• A2AR
• AChR
• autoimmune disease
• EAMG
• Th subsets

The adenosine A2A receptor (A2AR) is the major cellular adenosine receptor commonly associated with immunosuppression. Here, we investigated whether A2AR activation holds the potential for impacting the severity of experimental autoimmune myasthenia gravis (EAMG) induced following immunization of Lewis rats with the acetylcholine receptor (AChR) R97116 peptide. This report demonstrates reduced A2AR expression by both T cells and B cells residing in spleen and lymph nodes following EAMG induction. A2AR stimulation inhibited anti-AChR antibody production and proliferation of AChR-specific lymphocytes in vitro. Inhibition was blocked with the A2AR antagonists or protein kinase A inhibitor. We also determined that the development of EAMG was accompanied by a T-helper cell imbalance that could be restored following A2AR stimulation that resulted in increased Treg cell levels and a reduction in Th1-, Th2-, and Th17-cell subtypes. An EAMG-preventive treatment regimen was established that consisted of (2-(p-(2-carbonylethyl)phenylethylamino)-5-N-ethylcarboxamidoadenosine) (CGS21680; A2AR agonist) administration 1 day prior to EAMG induction. Administration of CGS21680 29 days post EAMG induction (therapeutic treatment) also ameliorated disease severity. We conclude that A2AR agonists may represent a new class of compounds that can be developed for use in the treatment of myasthenia gravis or other T-cell- and B-cell-mediated autoimmune diseases.

• 出版日期2012-5
• 单位哈尔滨医科大学